

New VHL Regulatory Pathways and Therapeutic Implications in ccRCC

Qing Zhang

Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA

VHL is the most important tumor suppressor in kidney cancer. VHL loss leads to stabilization of HIF2 α , which contributes largely to the development of clear cell renal cell carcinoma (ccRCC). Recent reports showed that the specific HIF2 α inhibitor PT2399 inhibits primary tumor growth and invasion of a subset of kidney cancer. However, a significant portion of kidney cancer remains resistant to HIF2 α inhibitor treatment, highlighting the importance of identifying additional therapeutic vulnerabilities of VHL-deficient kidney cancer. In this talk, I will discuss some of our latest results on new VHL regulatory pathways, including ZHX2, SFMBT1 and TBK1. I will discuss on they may contribute to ccRCC tumorigenesis and their therapeutic implications.